CD274 and neoplasm: The major findings of this study were: Tumor mutation burden was greater in patients with durable clinical benefit than in those with non-durable clinical benefit; Durable clinical benefit was more common, and PFS was longer in patients at increasing tumor mutation burden; the fraction of copy number-altered genome was highest in patients with non-durable clinical benefit; tumor mutation burden and PD-L1 expression level were independent variables, and a combined tumor mutation burden and PD-L1 expression enriched for benefit to treatment with immune checkpoint inhibitors [299].